StockGuru News: Bio-Matrix Scientific Group Inc. Appoints Daniel Gomez as Director of Engineering

Bio-Matrix Scientific Group Inc. Appoints Daniel Gomez as Director of Engineering Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) SAN DIEGO–(BUSINESS WIRE)–Sept. 19, 2006–Bio-Matrix Scientific Group Inc. (OTCBB:BMSN – News), a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced today the appointment of Daniel Gomez as Director of Engineering. Mr. Gomez will be responsible for the design and engineering of medical devices and the implementation of new technologies. Mr. Gomez is an industry veteran and brings over thirty-five years of experience in all facets of manufacturing, most recently serving as President of Collective Technologies, Inc., where he was responsible for leadership, while overseeing the overall strategy of the company. Brian Pockett, Managing Director and COO, stated, “Dan brings strong technical expertise, in-depth knowledge of the manufacturing industry and a proven ability to lead innovative solutions to meet our clients’ needs going forward.” This press release is available on the company’s official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to BMSN@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time. About Bio-Matrix Scientific Group Inc. Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry. DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. Contact: Bio-Matrix Scientific Group Inc. Investor Relations, 619-398-3517 info@BMSNonline.com or AGORA Investor Relations BMSN@agoracom.com http://www.agoracom.com/IR/Bio-Matrix Source: Bio-Matrix Scientific Group Inc. View the StockGuru Profile for Bio-Matrix Scientific Group: http://www.stockguru.com/profiles/bmsn/ We Invite you to Visit the All New StockGuru Blog! Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks. Click HERE to visit the Blog, or go to: http://stockguru.com/blog/ StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $10,000 for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.